MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples